Improved disease-free survival with adjuvant radiotherapy in early-stage endometrial cancer: 10-year outcome analysis

Arslan S. A. , Avci G. G. , Akkas E. A. , Guney Y.

Journal of Contemporary Brachytherapy, vol.12, no.6, pp.572-578, 2021 (Journal Indexed in SCI Expanded) identifier

  • Publication Type: Article / Abstract
  • Volume: 12 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.5114/jcb.2020.101690
  • Title of Journal : Journal of Contemporary Brachytherapy
  • Page Numbers: pp.572-578


© 2020 Termedia Publishing House Ltd.. All rights reserved.Purpose: The purpose of this study was to evaluate long-term treatment outcomes and prognostic factors affecting survival of patients with early-stage endometrial carcinoma. Material and methods: Data of 311 patients with FIGO stage I-II endometrial cancer, curatively treated at two different tertiary centers between June 2001 and December 2016 were retrospectively reviewed. The patients had primary surgery, 74 (24%) received no further treatment, 4 (1%) obtained chemotherapy only, 234 (75%) received radiotherapy, and 24 (7%) received both. Results: Median follow-up time was 102 (range, 3-205) months. During this period, 68 (21.9%) patients died. 5-year and 10-year disease-free survival (DFS) were 76% and 74.3%, respectively. In multivariate analysis, lower uterine segment invasion positivity and no adjuvant radiotherapy were determined as independent unfavorable prognostic factors for DFS. The 5-year and 10-year disease-specific survival (DSS) were 86.8% and 82.2%, respectively. For DSS, high-grade, lymphovascular space invasion positivity, stage II, ⪚ 65 age, and no adjuvant radiotherapy were found to be independent unfavorable prognostic markers. Conclusions: The findings of our cohort have confirmed the importance of adjuvant radiotherapy on long-term early-stage endometrial carcinoma outcome.